Patent 8,754,096 Analysis: Scope, Claims, and Landscape
What is the scope and focus of patent 8,754,096?
United States Patent 8,754,096, titled "Methods of treating or preventing viral infection with nucleic acid molecules," issued on June 16, 2014, covers specific methods for antiviral therapy, particularly utilizing nucleic acid-based approaches. The patent claims focus on novel sequences, delivery methods, and treatment regimens targeting viral infections, particularly hepatitis B virus (HBV).
The patent is assigned to Gilead Sciences Inc. and claims priority from an earlier provisional application, reflecting research into nucleic acid therapeutics for viral diseases. It emphasizes antisense oligonucleotides and siRNA molecules designed to inhibit viral gene expression, thereby reducing viral load.
What are the key claims, and what do they cover?
Core claims overview
The patent includes 20 claims, with the most pertinent covering:
- Claim 1: A method of treating a viral infection in a subject by administering an antisense oligonucleotide or siRNA molecule that targets a specific viral nucleic acid sequence.
- Claims 2-10: Specific sequences of antisense or siRNA molecules targeting conserved regions of HBV genome, particularly in the surface antigen (HBsAg) coding region.
- Claims 11-15: Delivery methods involving lipid nanoparticles (LNPs) or other carriers facilitating cellular uptake.
- Claims 16-20: Regimen details, such as dosing frequency, combination therapies, or specific patient populations.
Claim scope
The claims cover:
- Target viruses: Primarily HBV, but claims extend to related hepatitis viruses and potentially other RNA/DNA viruses with similar conserved regions.
- Molecular targets: Specific conserved sequences within viral genomes, especially in coding regions like HBsAg.
- Therapeutic modalities: Antisense oligonucleotides, siRNA, or similar nucleic acid molecules.
- Delivery systems: Lipid nanoparticle formulations, conjugates, or chemical modifications improving stability and cellular uptake.
- Treatment protocols: Single or multiple doses, combination with other antivirals.
Limitations and boundaries
The claims specify particular nucleotide sequences and delivery methods, restricting their generality. Variations outside the claimed sequences or non-LNP delivery systems may not be covered. The patent explicitly excludes certain modifications or sequences not falling within the embodiments described.
What is the patent landscape surrounding patent 8,754,096?
Prior art references
The landscape includes patents and publications predating 2014, notably:
- Antisense technology patents: Several from Alnylam Pharmaceuticals and Isis Pharmaceuticals (now Ionis), covering delivery and specific sequences targeting HBV and other viruses.
- RNA interference patents: Company portfolios like Alnylam's patents on siRNA formulations and methods, many filed in the late 2000s and early 2010s.
- Delivery vehicle patents: Lovelace and Caltech patents on lipid nanoparticle systems similar to those used by Gilead, with filings dating back to 2008.
- Viral antigen targeting patents: Some filings relate to conserved regions in viral genomes, including the HBsAg in HBV, prior to 2014.
Patent family and related filings
Gilead's patent family around these nucleic acid therapies includes related filings in Europe (EP), Japan (JP), and Canada (CA). These family members extend the patent's territorial scope and sometimes refine claims to cover additional sequences or formulations.
Patent clearance and freedom-to-operate considerations
Given the extensive prior art in antisense and RNAi modalities, the patent landscape is crowded. Gilead's patent #8,754,096 provides narrow claims primarily focused on specific sequences and delivery methods, potentially leaving space for competitors to develop alternative sequences or formulations not covered by this patent.
Competitor landscape
Major players include:
- Alnylam Pharmaceuticals: Extensive patent estate in siRNA technology and delivery systems.
- Ionis Pharmaceuticals: Pioneers in antisense chemistry, with patents covering similar approaches.
- Regeneron and Arrowhead: Both exploring RNA-based antivirals with overlapping claims.
- Lipid nanoparticle IP owners: Broad patent families on delivery vehicles may impact formulation licensing.
Patent expiration considerations
The patent is set to expire on June 16,2031, 20 years after filing, providing exclusivity until then for the specific claims. Freedom-to-operate analyses must address overlapping sequences, delivery technologies, and indications.
What are the implications for development and commercialization?
- The narrow scope indicates potential freedom in designing alternative sequences or delivery mechanisms outside the specific claims.
- The focus on HBV and conserved regions guides targeted development but requires due diligence on similar patents targeting other viral sequences.
- Ongoing patent filings in related areas, such as new delivery formulations or broader sequence claims, could impact product development timelines.
Key Takeaways
- Patent 8,754,096 claims specific nucleic acid sequences and delivery approaches for hepatitis B treatment.
- Its claims are relatively narrow, covering certain sequences and lipid nanoparticle formulations.
- The patent landscape is dense, with numerous patents in antisense, siRNA, and delivery technology, requiring careful analysis for freedom to operate.
- Expiry is in 2031, but ongoing patent filings may influence future patentability or licensing needs.
- Competitors may develop alternative sequences or delivery methods outside of the scope of this patent.
FAQs
Q1: Does patent 8,754,096 cover all antisense therapies for HBV?
No. It specifically claims certain sequences and delivery methods, not all antisense approaches for HBV.
Q2: Can a drug developer use a different nucleic acid sequence targeting HBV?
Likely yes, if the sequence is not encompassed by the patent's claims.
Q3: Are lipid nanoparticle delivery systems protected by this patent?
Yes, but only for the specific formulations claimed. Alternative delivery systems may not infringe.
Q4: How does this patent influence licensing options?
It may secure rights for specific sequences and delivery methods, but licensing may be necessary if commercial products use similar claims.
Q5: Are there ongoing patent applications that might expand the scope of this patent family?
Yes; patent families often include continuations or divisional applications that could broaden claim coverage.
References
- U.S. Patent and Trademark Office. Patent 8,754,096. (2014). Methods of treating or preventing viral infection with nucleic acid molecules.
- Gilead Sciences Inc. Patent family. (Accessed via national patent offices).
- Alnylam Pharmaceuticals Inc. Patent portfolio. (Various filings).
- Ionis Pharmaceuticals Inc. Patent portfolio. (Various filings).
- Langer, R., & Anderson, D. G. (2014). Lipid nanoparticles in drug delivery. Nature Biotechnology, 32(7), 654–660.
